(3.236.231.61) 您好!臺灣時間:2021/05/11 16:39
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:吳思遠
研究生(外文):Szu-Yuan Wu
論文名稱:B型肝炎病人使用statin和metformin對癌症風險之世代研究
論文名稱(外文):Cancer Risk of HBV Patients with Statin and Metformin A Population-Based Cohort Study
指導教授:陳為堅陳為堅引用關係
指導教授(外文):Wei-Jen Chen
口試委員:簡國龍黃奇英劉如濟
口試委員(外文):Kuo-Liong CheinChi-Ying HuangJu-chi Liu
口試日期:2013-07-26
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:公共衛生碩士學位學程
學門:醫藥衛生學門
學類:公共衛生學類
論文種類:學術論文
論文出版年:2012
畢業學年度:101
語文別:英文
論文頁數:71
中文關鍵詞:B型肝炎病毒癌症statins類藥物metformin世代研究
外文關鍵詞:Hepatitis B viruscancerStatinMetforminCohort Studies.
相關次數:
  • 被引用被引用:0
  • 點閱點閱:496
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
中文摘要
研究目的: HBV感染者可能會增加肝臟和非肝臟癌症的發病率。可能的原因包括HBV感染的直接效應,在宿主的免疫系統因為慢性感染而造成免疫系統的變化。因此,服用statins類藥物或metformin可以降低炎症浸潤且降低發炎反應,導致減少癌症的形式有可能的。使用statins類藥物和metformin與癌症風險之間的連接,目前還不清楚,我們的研究在調查是否statins類藥物和metformin的使用是否有可能降低HBV感染患者的癌症發病率。本研究的目的是假設statins類藥物和metformin可以減少癌症在HBV感染相關慢性肝病患者的發病率。
方法: 使用台灣健保資料庫從2000年到2008年,這個世代研究包括HBV患者(N=71,847),從2000年1月1日和2008年12月31日之間的診斷記錄。直到2008年年底。 HBV患者的statins類藥物和/或metformin的用法和癌症的風險之間的相關性進行了分析。使用Cox風險回歸分析來評估已知的干擾因素調整後的發病率。利用Kaplan-Meier檢驗statins類藥物或metformin服用後的癌症的累積風險。
結果: 一共有71,824 HBV感染患者被納入世代研究。我們的研究結果發現metformin或statins類藥物的使用,可以減少癌症的發病率。尤其在兩藥同時服用時癌症減少更明顯。HBV患者只服用statins類藥物的話,所有的癌症,肝癌,肝癌,肺癌,胃癌,大腸癌,食道癌,前列腺癌和不常見的癌症的發生率均有達統計意義的下降。我們似乎可以觀察到statins類藥物和metformin聯合使用時具有協同效應,可以發現在單獨使用statins類藥物或metformin時無統計意義的癌症,在女性HBV感染患者的乳腺癌,胰腺癌,乳腺癌和子宮頸癌發生率有達統計意義的下降。而男性患者中的大腸癌也有達統計意義的下降。在劑量使用上也發現了具有劑量依賴效應。
結論: 我們的世代研究發現statins類藥物和metformin對B肝帶原者中具有其癌症保護作用。我們的研究顯示,statins類藥物或metformin在降低癌症的發病率與劑量反應效應上均具備其正向且獨立的化學預防效果。且合併使用statins和metformin時,在多種癌症上面顯現出加成或是具有藥物協同的抗癌效果。


Abstract
Background: Chronic infection with hepatitis B virus (HBV) often causes chronic inflammation of the liver with an increased incidence of hepatocellular carcinoma. HBV-infected individuals also may be at increased incidence of non-liver cancers. Taking a statin or metformin may decrease inflammation and infiltration, which may, as a result, reduce the risk of liver cancer or other major cancers in patients with HBV infection. The purpose of this study was to evaluate the hypothesis that a statin and metformin could reduce the incidence of liver cancer (HBV) or non-liver cancers in patients with hepatitis B virus.
Method: Using the Taiwan Longitudinal Health Insurance Database 2000 to 2008, this cohort study comprised patients with a recorded diagnosis of HBV (N=71,847) between January 1, 2000 and December 31, 2008. Each patient was followed until the end of 2008. The occurrence of HCC or a non-liver cancer was evaluated in patients who either were or were not taking a statin or metformin. Cox proportional hazard regressions were used to evaluate the cancer incidence after adjusting for known confounding factors.
Results: A total of 71,824 HBV-infected patients comprised the study cohort. Our study showed that either metformin or statin use was associated with a reduction in the incidence of cancer. This was most prominent in patients taking both a statin and metformin. The adjusted HRs for patients using only a statin were 0.52 (95% CI, 0.48 to 0.57) for all cancers, 0.28 (95% CI, 0.23 to 0.35) for liver cancers, and 0.63 (95% CI, 0.57 to 0.70) for non-liver cancers. Patients taking only metformin had risk-adjusted HRs of 0.82 (95% CI, 0.75 to 0.90) for all cancers, 0.97 (95% CI, 0.84 to 1.14) for liver cancers, and 0.75 (95% CI, 0.67 to 0.84) for non-liver cancers. A dose-dependent effect of statin use for chemoprevention was observed for all cancers, including both liver cancer and non-liver cancers. A dose-dependent effect of metformin was also seen in liver cancers and non-liver cancers without stratification into different cDDDs of statin use.
Conclusion: This population-based cohort study investigated the protective effect of a statin and metformin against cancer events in the patients with HBV infection. Our study demonstrated that either a statin or metformin were independent chemo-preventive agents with a dose-response effect in reducing the incidence of cancer with a dose-response effect of the agents and an additive or synergistic effect of combining a statin and metformin use in reducing the incidence of many cancers.


Contents
Chinese Abstract...............................................................................................................i
Abstract.............................................................................................................................ii
Contents............................................................................................................................1
List of tables & figures.....................................................................................................2
List of appendix................................................................................................................3
Chapter 1 Introduction......................................................................................................5
Chapter 2 Methods............................................................................................................7
Chapter 3 Results............................................................................................................13
Chapter 4 Discussion......................................................................................................18
Tables..............................................................................................................................28
Reference........................................................................................................................37
Appendix........................................................................................................................45


References
1.Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA: Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. International Journal of Epidemiology 2005, 34(1):132-137.
2.Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clinical Cancer Research 2003, 9(1):10-19.
3.Wong WW, Dimitroulakos J, Minden MD, Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16(4):508-519.
4.Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for Diabetic Nephropathy. Proceedings of the National Academy of Sciences 2002, 99(12):8301-8305.
5.Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, Lorz C, Diaz C, Hernandez G, Egido J: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003, 108(12):1506-1513.
6.Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21(11):1712-1719.
7.Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE: Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003, 24(3):453-459.
8.Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proceedings of the National Academy of Sciences 1999, 96(14) : 7797 - 7802.
9.Mallat A, Preaux AM, Blazejewski S, Dhumeaux D, Rosenbaum J, Mavier P: Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 1994, 20 (6): 1589 - 1594.
10.Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF: Metformin and cancer therapy. Current Opinion in Oncology 2012, 24(1):103-108.
11.Santos CR, Schulze A: Lipid metabolism in cancer. The FEBS Journal 2012, 279(15):2610-2623.
12.El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126(2):460-468.
13.Renehan AG, Frystyk J, Flyvbjerg A: Obesity and cancer risk: the role of the insulin-IGF axis. Trends in Endocrinology and Metabolism 2006, 17(8):328-336.
14.Hess D, Chisholm JW, Igal RA: Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One 2010, 5(6):e11394.
15.Gray-Bablin J, Rao S, Keyomarsi K: Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Research 1997, 57(4):604-609.
16.Rao S, Lowe M, Herliczek TW, Keyomarsi K: Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998, 17(18):2393-2402.
17.Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S, Hosobe S, Tsukada T, Miura K et al: Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Research 2008, 68(4):1003-1011.
18.Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL: Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. Journal of the National Cancer Institue 2011, 103(19):1461-1468.
19.Bardou M, Barkun A, Martel M: Effect of statin therapy on colorectal cancer. Gut 2010, 59(11):1572-1585.
20.Dale KM, Coleman CI, Henyan NN, Kluger J, White CM: Statins and cancer risk: a meta-analysis. JAMA 2006, 295(1):74-80.
21.Bonovas S, Filioussi K, Flordellis CS, Sitaras NM: Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. Journal of Clinical Oncology 2007, 25(23):3462-3468.
22.Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32(9):1620-1625.
23.Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S: Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 2010, 3(11):1451-1461.
24.Noto H, Goto A, Tsujimoto T, Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012, 7(3):e33411.
25.WHO Collaborating Center for Drugs Statistics Methodology: ATC Index with DDDs 2003. Oslo, Norway, WHO, 2003.
26.Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330 (7503) : 1304 - 1305.
27.Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G et al: Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World Journal of Gastroenterology 2009, 15(20):2506-2511.
28.Donadon V, Balbi M, Mas MD, Casarin P, Zanette G: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver International 2010, 30(5):750-758.
29.Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL et al: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116(8):1938-1946.
30.Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC: Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. The American Journal of Gastroenterology 2012, 107(1):46-52.
31.Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8(6):909-915.
32.Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009, 8(1):88-96.
33.Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA: mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clinical & Translational Oncology 2009, 11(7):455-459.
34.Belda-Iniesta C, Pernia O, Simo R: Metformin: a new option in cancer treatment. Clinical & Translational Oncology 2011, 13(6):363-367.
35.Browne GJ, Finn SG, Proud CG: Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. The Journal of Biological Chemistry 2004, 279(13):12220-12231.
36.Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000, 103(2):253-262.
37.Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115(5):577-590.
38.Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell 2008, 30(2):214-226.
39.Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B: Diabetes mellitus and breast cancer. The Lancet Oncology 2005, 6(2):103-111.
40.Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M: Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British Journal of Cancer 2005, 92(11):2076-2083.
41.Larsson SC, Orsini N, Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute 2005, 97(22):1679-1687.
42.Friberg E, Orsini N, Mantzoros CS, Wolk A: Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007, 50(7):1365-1374.
43.Becker S, Dossus L, Kaaks R: Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Archives of Physiology and Biochemistry 2009, 115(2):86-96.
44.Schroder M, Kaufman RJ: The mammalian unfolded protein response. Annual Review of Biochemistry 2005, 74:739-789.
45.Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin-Ya K, Tsuruo T, Tomida A: Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Research 2009, 69(10):4225-4234.
46.Dilman VM, Berstein LM, Ostroumova MN, Fedorov SN, Poroshina TE, Tsyrlina EV, Buslaeva VP, Semiglazov VF, Seleznev IK, Bobrov Yu F et al: Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 1982, 39(1):13-19.
47.Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y: Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460(7251):103-107.
48.Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research 2009, 69(19):7507-7511.
49.Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA: The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment 2011, 126(2):355-364.
50.Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA: Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010, 9(18):3807-3814.
51.Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
52.Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA: Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010, 9(22):4461-4468.
53.Tsan YT, Lee CH, Wang JD, Chen PC: Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Journal of Clinical Oncology 2012, 30(6):623-630.
54.Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006, 44(1):117-125.
55.Lehman DM, Lorenzo C, Hernandez J, Wang CP: Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012, 35(5):1002-1007.
56.Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L: Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. International Journal of Cancer Journal International Du Cancer 2012, 130(7):1639-1648.
57.Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Archives of Internal Medicine 2006, 166(17):1871-1877.
58.Lai MS, Hsieh MS, Chiu YH, Chen TH: Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006, 43(6):1295-1302.
59.Torisu Y, Ikeda K, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Kawamura Y, Yatsuji H, Suzuki F, Suzuki Y et al: Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report. Hepatology Research 2007, 37(7):517-523.
60.Tazawa J, Maeda M, Nakagawa M, Ohbayashi H, Kusano F, Yamane M, Sakai Y, Suzuki K: Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Digestive Diseases and Sciences 2002, 47(4):710-715.
61.Ben Q, Cai Q, Li Z, Yuan Y, Ning X, Deng S, Wang K: The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 2011, 47(2):248-254.
62.El-Serag HB, Hampel H, Javadi F: The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical Gastroenterology and Hepatology 2006, 4(3):369-380.
63.Heidemann C, Boeing H, Pischon T, Nothlings U, Joost HG, Schulze MB: Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. European Journal of Epidemiology 2009, 24(6):281-288.
64.Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, Weiss NS: Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. American Journal of Epidemiology 2008, 167(5):607-614.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔